share_log

Progyny (NASDAQ:PGNY) Issues Earnings Results

kopsource ·  Aug 7, 2022 22:12

Progyny (NASDAQ:PGNY – Get Rating) issued its quarterly earnings data on Thursday. The company reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.05 by $0.04, Briefing.com reports. Progyny had a net margin of 7.39% and a return on equity of 18.11%. The firm had revenue of $195.00 million for the quarter, compared to analyst estimates of $190.51 million. During the same quarter in the previous year, the business posted $0.19 EPS. The firm's revenue was up 51.5% compared to the same quarter last year.

Progyny Price Performance

Shares of PGNY stock opened at $41.15 on Friday. Progyny has a 12 month low of $25.67 and a 12 month high of $68.32. The firm has a market capitalization of $3.78 billion, a P/E ratio of 89.46, a P/E/G ratio of 21.71 and a beta of 1.85. The company's fifty day moving average price is $30.23 and its two-hundred day moving average price is $37.32.

Get Progyny alerts:

Insiders Place Their Bets

In other Progyny news, Chairman David J. Schlanger sold 1,452 shares of the business's stock in a transaction on Monday, June 27th. The shares were sold at an average price of $31.21, for a total value of $45,316.92. Following the transaction, the chairman now owns 82,548 shares in the company, valued at approximately $2,576,323.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Chairman David J. Schlanger sold 1,452 shares of the company's stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $31.21, for a total value of $45,316.92. Following the sale, the chairman now owns 82,548 shares in the company, valued at approximately $2,576,323.08. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Norman Payson sold 6,618 shares of the company's stock in a transaction dated Wednesday, May 11th. The shares were sold at an average price of $33.45, for a total transaction of $221,372.10. Following the completion of the sale, the director now owns 490,828 shares in the company, valued at approximately $16,418,196.60. The disclosure for this sale can be found here. Insiders have sold 41,240 shares of company stock worth $1,291,601 in the last quarter. 14.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Progyny

Institutional investors have recently modified their holdings of the stock. Vontobel Holding Ltd. bought a new stake in shares of Progyny during the 1st quarter valued at about $1,969,000. Yousif Capital Management LLC grew its position in shares of Progyny by 1.1% during the 1st quarter. Yousif Capital Management LLC now owns 37,264 shares of the company's stock valued at $1,915,000 after buying an additional 392 shares during the last quarter. Eaton Vance Management grew its position in shares of Progyny by 99.8% during the 1st quarter. Eaton Vance Management now owns 32,071 shares of the company's stock valued at $1,649,000 after buying an additional 16,018 shares during the last quarter. Natixis Advisors L.P. grew its position in shares of Progyny by 47.3% during the 1st quarter. Natixis Advisors L.P. now owns 29,595 shares of the company's stock valued at $1,521,000 after buying an additional 9,497 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in shares of Progyny by 10.5% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 25,519 shares of the company's stock valued at $1,312,000 after buying an additional 2,433 shares during the last quarter. Institutional investors and hedge funds own 82.51% of the company's stock.

About Progyny

(Get Rating)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Further Reading

  • Get a free copy of the StockNews.com research report on Progyny (PGNY)
  • MarketBeat: Week in Review 8/1 – 8/5
  • How to Use High Beta Stocks to Maximize Your Investing Profits
  • Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
  • Why Apple Could Be At All-Time Highs By Year End
  • Beyond Meat Is Not Beyond Hope, And It's Cheap

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment